# Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01940965` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01940965](<https://clinicaltrials.gov/study/NCT01940965>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01940965

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

## Technical summary

Registry record NCT01940965. Non-randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 294 participants (enrolled count; ClinicalTrials.gov record NCT01940965, source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01940965, source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01940965, source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01940965, source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01940965, source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01940965-2015-08-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): lixisenatide AVE0010
- Intervention (Drug): biguanide
- Intervention (Drug): TZD
- Intervention (Drug): alpha-GI
- Intervention (Drug): glinide
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 44d7677079908946f34cb3048c59d909305bc6a9f2ee7ef556fef03476af2d16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
